Navigation Links
Low-Dose Oral Contraceptives May Increase Risk of Pelvic Pain During Sexual Climax
Date:5/3/2013

SAN DIEGO, May 3, 2013 /PRNewswire-USNewswire/ -- Low-dose (low estrogen) oral contraceptives (OCPs) may increase a woman's risk for chronic pelvic pain symptoms (CPPS) and even pain during sexual climax, according to a new study. This study will be presented to reporters at the 108th Annual Scientific Meeting of the American Urological Association (AUA) during a press conference at the San Diego Convention Center, San Diego, CA on May 7 at 11:00 a.m. PDT.

Oral contraceptives have been available in the United States for more than half a century and while considered innocuous today (because of lower doses of estrogen) than even 25 years ago, their effects on conditions such as CPPS are not yet fully understood. Therefore researchers from New York University and Waitemata District Health Board in Auckland, New Zealand conducted a study to compare CPPS between young women who are current OCP users and non-users.

Researchers used data collected from an anonymous, Internet-based survey of women 18-39 years of age within large university populations. The researchers did not include women who were pregnant or had a history of endometriosis or pelvic pain, and gathered demographic data as well as information on the type of OCP, duration of use, and indication for usage. Once data was collected, respondents were sorted into the following groups:

  • Not using an OCP
  • Taking a low-dose of estrogen
  • Taking a normal dose (>20mcg) of estrogen

Additionally, respondents were classified as having CPPS if their total index pain score was greater than or equal to four. The researchers then compared the responses between the groups.

Of the 932 respondents who were eligible for the study, 605 were categorized as non-OCP users and 327 were categorized as OCP users, with 169 using low-dose and 171 using normal dose OCPs. The researchers found significant differences in the incidence of individual pelvic pain symptoms between OCP users and non−users and further differences with low−dose use. Specifically, results showed:

  • Low−dose OCP users were more likely to report pelvic pain symptoms and more likely to have CPPS than non−users (27.1 percent vs. 17.5 percent, p=0.045).
  • Low-dose OCP users had almost twice the incidence of pain or discomfort during or after sexual climax compared to controls, and there was no difference between normal dose OCP users and controls.
  • Normal dose OCP users were less likely to have pelvic pain symptoms than non OCP users.
  • Forty-four percent of respondents reported onset of pain after beginning OCP use and were more likely to fulfill CPPS criteria than those who had symptoms prior to OCP use (62 percent vs. 30.3 percent, p<0.001).

"This study reveals valuable insights into the relationship between oral contraceptives, pelvic pain and how effects may differ depending on hormone dosage," said Dr. Kristene Whitmore , chair of urology and female pelvic medicine and reconstructive surgery and professor of urology and OBGYN at Drexel University College of Medicine. "It also has been recently reported that patients have an increased incidence of vulvodynia when taking low dose OCPs, therefore additional research is needed to determine if the chronic pelvic pain noted in this study is related to vulvar pain or the hormone dosage."

About the American Urological Association: Founded in 1902 and headquartered near Baltimore, Maryland, the American Urological Association is a leading advocate for the specialty of urology, and has more than 19,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.


'/>"/>
SOURCE American Urological Association
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
2. Contraceptives Market to 2018 - Safety Concerns Plague Drospirenone-containing Birth Control Pills and Long-term Use of Estrogen
3. Mylan Reports a 19% Increase in First Quarter 2013 Adjusted Diluted EPS to $0.62
4. Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
5. HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
6. Chindex-Fosun Pharma Joint Venture, Chindex Medical, To Participate in Acquisition of Alma Lasers; Fosun Pharma Increases Investment in Chindex Medical
7. Amgens First Quarter 2013 Revenues Increased 5 Percent To $4.2 Billion And Adjusted Earnings Per Share (EPS) Increased 22 Percent To $1.96
8. Covance Expands Singapore Central Laboratory by 50 Percent to Meet Clients Increased Asia Pacific Focus
9. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
10. Wright, Biomet, Stryker Hip Recall Settlement Funding News: Legal-Bay To Increase Funding Amounts Up to $50K
11. Western European Endoscopic Devices Market to Benefit from Increase in Minimally Invasive Surgeries, Says Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 CENTRO DE ... article 157, paragraph 4 of Law 6,404/76 and Instruction ... hereby informs its shareholders and the market in general ... its subsidiary Centro de Diagnosticos por Imagem Ltda. (" ... 100% interest in RADIOLOGISTAS ASSOCIADOS LTDA. (" Partnership " ...
(Date:3/23/2017)... 2017 Ascendis Pharma A/S (Nasdaq: ASND), a ... address significant unmet medical needs in rare diseases, today ... and webcast on Monday, April 3 during ENDO 2017, ... Orlando, Florida , to discuss new data ... Hormone, TransCon PTH and TransCon CNP). Ascendis ...
(Date:3/23/2017)... - INVICTUS MD STRATEGIES CORP. ("Invictus MD" or the "Company") ... that AB Laboratories Inc. ("AB Labs") has successfully completed ... the Access to Cannabis for Medical Purposes Regulations ("ACMPR") ... The facility, which was licensed for Cultivation ... at half capacity, with full production capacity scheduled by ...
Breaking Medicine Technology:
(Date:3/23/2017)... Segundo, CA (PRWEB) , ... March 23, 2017 ... ... Verisys FACIS Monthly Monitoring Healthcare products at competitive pricing. Verisys ... source sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are delighted ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... non-steroidal skincare products, was awarded as winners of American Dreams & Good Housekeeping ... was hosted jointly by HSN and Good Housekeeping. , Steven Wang, MD ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored to host Shriners and ... will be located in the Main West Entrance of The Boulevard (in front of ... appointment is necessary and each child with a parent or guardian will be photographed ...
(Date:3/23/2017)... ... March 23, 2017 , ... “Beyond and Back”: a true-life ... is the creation of published author Bonetta Rose, a wife, mother and grandmother committed ... Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ogden Clinic, ... patient - centric payment system, to expand its focus on patient care by ... financial experience. , “At Ogden Clinic, we are working to become a ...
Breaking Medicine News(10 mins):